Buscar
AIM ImmunoTech Inc
AIMAñadir a la lista de seguimiento
0.257USD
+0.022+9.45%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.12MCap. mercado
PérdidaP/E TTM
Más Datos de AIM ImmunoTech Inc Compañía
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Información de AIM ImmunoTech Inc
Símbolo de cotizaciónAIM
Nombre de la empresaAIM ImmunoTech Inc
Fecha de salida a bolsaJul 12, 1996
Director ejecutivoEquels (Thomas K)
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 12
Dirección2117 Sw Highway 484
CiudadOCALA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal32801
Teléfono13524487797
Sitio Webhttps://aimimmuno.com/
Símbolo de cotizaciónAIM
Fecha de salida a bolsaJul 12, 1996
Director ejecutivoEquels (Thomas K)
Ejecutivos de AIM ImmunoTech Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de AIM ImmunoTech Inc?
Los cinco principales accionistas de AIM ImmunoTech Inc son: Mr. Thomas K. Equels, Esq., J.D.
¿Cuántas instituciones poseen acciones de AIM ImmunoTech Inc (AIM)?
A fecha de 2026Q1, 57 instituciones poseen acciones de AIM ImmunoTech Inc, con un valor de mercado combinado de aproximadamente 105.74K, lo que representa el 1.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -74291.00.